Esperion Therapeutis.Inc. buy Bank of America Co.
Summary
This prediction ended on 16.06.24 with a price of €2.69. The BUY prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc. saw massive gains of 111.30%. Bank_of_America_Co_ has a follow-up prediction for Esperion Therapeutis.Inc., but this time predicts that Esperion Therapeutis.Inc. is a Sell. Bank_of_America_Co_ has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | 22.386% | 22.386% | 102.088% |
iShares Core DAX® | -1.471% | 1.895% | 25.178% |
iShares Nasdaq 100 | -0.486% | 4.395% | 29.415% |
iShares Nikkei 225® | -2.115% | 2.450% | 20.561% |
iShares S&P 500 | 0.394% | 3.118% | 29.456% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Current prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
20.06.24
20.06.25
22:26